Read More

Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 1,809,955 Shares Of Common Stock At A Pur…

Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted

BPTH

Read More

What’s Going On With Bio-Path Stock?

Bio-Path Holdings shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).  

BPTH